在CD-1小鼠中,普罗巴诺洛尔阻断了甲基胺无条件和有条件的过活效应
1Psychology Department and Neuroscience Program, Dickinson College, Carlisle, PA, USA.
Behavioural pharmacology
|July 18, 2023
概括
贝塔上腺系统在甲基胺引起的学会和药物诱导的多动性中起着关键作用. 使用普拉诺洛尔阻断β-上腺素受体显著降低了小鼠的这些效应.
科学领域:
- 神经药理学神经药理学
- 行为神经科学 行为神经科学
背景情况:
- 甲基胺诱导了直接的药理和学习过度活跃.
- 贝塔上腺系统是这些甲基胺效应的潜在调解者.
研究的目的:
- 调查β-上腺素受体系统在调解甲基胺诱导的无条件和有条件过活性的作用.
- 为了确定一种β-上腺素抗剂,即普拉诺洛尔能否阻断这些效应.
主要方法:
- 小鼠接受了为期8天的调节程序,交替进行室内和家庭子注射日.
- 在甲基胺或载体注射之前,小鼠接受了载体或普拉诺洛尔.
- 在最后一次调节课后48小时,评估了有条件的多动性.
主要成果:
- 根据剂量的不同,普罗普拉诺洛尔 (propranolol) 阻断了甲基胺引起的无条件 (药理) 过活性.
- 普罗巴诺洛尔还显著降低了与甲基胺暴露相关的有条件 (学习) 过活性.
- 这些发现强调了β-上腺系统在对甲基胺的直接和学习行为反应中的参与.
结论:
- 贝塔-上腺素受体系统在调解甲基胺的直接和学习过活效应方面发挥着关键作用.
- 针对β-上腺系统可能提供一种治疗策略,以减轻甲基胺诱导的行为变化.
相关概念视频
Adrenergic Agonists: Mixed-Action Agents
790
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
790
Adrenergic Agonists: Indirect-Acting Agents
1.7K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.7K
Drugs Affecting Neurotransmitter Release or Uptake
1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K
Drugs Acting on Autonomic Ganglia: Stimulants
1.4K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.4K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
893
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
893
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K


